PO.MCB10.01 · 分子与细胞生物学

靶向microRNA介导的铜稳态失调以增强胶质母细胞瘤瘤内对溶瘤单纯疱疹病毒-1的易感性

Targeting microRNA-mediated copper homeostasis dysregulation to enhance intratumoral susceptibility to oncolytic herpes simplex virus-1 in glioblastoma

编号 2060 展板 20 时间 4/20 09:00–12:00 区域 Section 25 主讲 Tae Jin Lee, PhD
分会场 MicroRNAs as Cancer Biomarkers, Therapeutic Targets, and Modulators of Treatment Response
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Tae Jin Lee1, Min Hye Noh1, Citu Citu2, Alexandra A. Miller1, Jiyeon Kim1, Grace Nguyen1, Minxin Huang1, Amanda S. Kouaho1, Stephanie M. Bean1, Dohyoung Lee1, Lily Nguyen1, E. Antonio Chiocca3, Zhongming Zhao2, Ji Young Yoo1

1Department of Neurosurgery, UT Health Houston, Houston, TX,2Center for Precision Health, UT Health Houston, Houston, TX,3Department of Neurosurgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

摘要 Abstract

中文摘要
胶质母细胞瘤(GBM)是一种WHO IV级星形细胞瘤,以弥漫浸润、快速增殖和对传统疗法的耐药为特征,导致患者结局惨淡。溶瘤病毒疗法,尤其是利用经基因工程改造的溶瘤单纯疱疹病毒-1(oHSV),已展现出肿瘤选择性溶解和免疫原性细胞死亡。尽管临床前数据令人鼓舞,但由于GBM肿瘤微环境(TME)内部固有耐药机制尚不明确,临床疗效仍然有限。我们的研究鉴定出microRNA-155(miR-155)为oHSV治疗耐药的关键调控因子。我们发现GBM中miR-155表达相比低级别胶质瘤升高,且与不良预后和对OV治疗反应降低相关。这些发现进一步得到癌症基因组图谱(TCGA)数据的支持。异位过表达miR-155显著减弱了oHSV复制和致细胞病变效应。转录组分析和通路富集分析显示,miR-155上调金属硫蛋白MT1E和MT1F,它们是细胞内铜隔离和抗病毒防御的关键调控因子。从机制上讲,miR-155通过MT1轴破坏铜稳态,损害病毒复制和治疗疗效。通过CRISPR/Cas9介导的敲除或基于锁核酸(LNA)的抑制对miR-155进行功能性消除,恢复了铜稳态、oHSV复制动力学,并增强了体外和原位GBM异种移植模型中的溶瘤作用,从而延长了生存期。这些数据表明,miR-155/MT1E-MT1F/铜信号轴代表了oHSV治疗的一个新型屏障。这项工作阐明了GBM中一条以往未被表征的抗病毒耐药通路,并验证了miR-155抑制作为增强oHSV疗效的合理治疗策略。我们的发现为克服固有耐药和推进病毒疗法在神经肿瘤学中的临床转化提供了机制框架。本摘要最初由作者撰写,随后使用生成式人工智能(AI)进行了编辑和修订。
查看英文原文 English abstract
Glioblastoma (GBM) is a WHO grade IV astrocytoma characterized by diffuse infiltration, rapid proliferation, and resistance to conventional therapies, resulting in dismal patient outcomes. Oncolytic virotherapy, particularly utilizing genetically engineered oncolytic herpes simplex virus-1 (oHSV), has demonstrated tumor-selective cytolysis and immunogenic cell death. Despite promising preclinical data, clinical efficacy remains limited due to poorly defined intrinsic resistance mechanisms within the tumor microenvironment (TME) of GBM. Our study identified microRNA-155 (miR-155) as a critical modulator of oHSV therapeutic resistance. We found elevated miR-155 expression in GBM compared to low-grade gliomas, which correlates with a poor prognosis and reduced response to OV therapy. These findings were further supported by The Cancer Genome Atlas (TCGA) data. Ectopic overexpression of miR-155 significantly attenuated oHSV replication and cytopathic effects. Transcriptomic profiling and pathway enrichment analyses revealed that miR-155 upregulates metallothioneins MT1E and MT1F , key regulators of intracellular copper sequestration and antiviral defense. Mechanistically, miR-155 disrupts copper homeostasis via the MT1 axis, impairing viral replication and therapeutic efficacy. Functional ablation of miR-155 via CRISPR/Cas9-mediated knockout or Locked Nucleic Acid (LNA)-based inhibition restored copper homeostasis, oHSV replication kinetics, and enhanced oncolysis in vitro and in orthotopic GBM xenograft models, resulting in prolonged survival. These data suggest that the miR-155/MT1E-MT1F/copper signaling axis represents a novel barrier to oHSV therapy. This work elucidates a previously uncharacterized antiviral resistance pathway in GBM and validates miR-155 inhibition as a rational therapeutic strategy to potentiate oHSV efficacy. Our findings provide a mechanistic framework for overcoming innate resistance and advancing the clinical translation of virotherapy in neuro-oncology. This abstract was originally written by the authors and then edited and revised with generative artificial intelligence (AI).
利益披露 Disclosure
T. Lee, None.. M. Noh, None.. C. Citu, None.. A. A. Miller, None.. J. Kim, None.. G. Nguyen, None.. M. Huang, None.. A. S. Kouaho, None.. S. M. Bean, None.. D. Lee, None.. L. Nguyen, None. E. Chiocca, Bionaut Laboratories Stock Option. Seneca Therapeutics Stock Option. Ternalys Therapeutics g., Board of Directors, non-salaried role), Stock Option. ReIgnite Therapeutics Stock Option. Z. Zhao, None.. J. Yoo, None.

← 返回 AACR 2026 检索